Big Pharma Split Stock Today
| PRM Stock | CAD 14.72 0.01 0.07% |
PerformanceGood
| Odds Of DistressSmall
|
Big Pharma is selling at 14.72 as of the 10th of February 2026; that is 0.07% down since the beginning of the trading day. The stock's open price was 14.73. Big Pharma has about a 37 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 12th of November 2025 and ending today, the 10th of February 2026. Click here to learn more.
Business Domain Financial Services | Classification Financials |
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada. BIG PHARMA operates under Asset Management classification in Canada and is traded on Toronto Stock Exchange.. The company has 1.22 M outstanding shares of which 3.23 K shares are at this time shorted by private and institutional investors with about 3.56 days to cover all short positions. More on Big Pharma Split
Moving together with Big Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Big Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Big Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Big Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Asset Management & Custody Banks, Financial Services, Financials, Capital Markets, Asset Management, Financial Services (View all Sectors) | ||||
Big Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Big Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsBig Pharma utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Big Pharma's leverage profile, showing how much of Big Pharma's resources are funded through borrowing.
| |||||
Big Pharma Split (PRM) is traded on Toronto Exchange in Canada . Big Pharma is listed under Asset Management & Custody Banks category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Big Pharma's market, we take the total number of its shares issued and multiply it by Big Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Big Pharma Split operates under Capital Markets sector and is part of Financials industry. The entity has 1.22 M outstanding shares of which 3.23 K shares are at this time shorted by private and institutional investors with about 3.56 days to cover all short positions.
Big Pharma generates negative cash flow from operations
Check Big Pharma Probability Of Bankruptcy
Big Pharma Historical Income Statement
Big Stock Against Markets
Big Stock Analysis Notes
The company has price-to-book ratio of 1.07. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Big Pharma Split recorded a loss per share of 1.95. The entity last dividend was issued on the 30th of January 2026. Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada. BIG PHARMA operates under Asset Management classification in Canada and is traded on Toronto Stock Exchange. To find out more about Big Pharma Split contact the company at 416-649-4541 or learn more at https://www.harvestportfolios.com/closed-end-funds.Big Pharma Split Investment Alerts
| The company reported the revenue of 1.85 M. Net Loss for the year was (538.62 K) with loss before overhead, payroll, taxes, and interest of (664.73 K). | |
| Big Pharma generates negative cash flow from operations | |
| Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - Stock Traders Daily |
Big Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Big Pharma's market, we take the total number of its shares issued and multiply it by Big Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Big Profitablity
Big Pharma's profitability indicators refer to fundamental financial ratios that showcase Big Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Big Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Big Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Big Pharma's profitability requires more research than a typical breakdown of Big Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.02) | (0.02) | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (0.05) | (0.04) |
Management Efficiency
Big Pharma Split has return on total asset (ROA) of (0.031) % which means that it has lost $0.031 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1564) %, meaning that it generated substantial loss on money invested by shareholders. Big Pharma's management efficiency ratios could be used to measure how well Big Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 10th of February 2026, Return On Tangible Assets is likely to grow to -0.02. In addition to that, Return On Capital Employed is likely to drop to 0. At this time, Big Pharma's Total Assets are very stable compared to the past year. As of the 10th of February 2026, Other Assets is likely to grow to about 31.8 M, while Net Tangible Assets are likely to drop about 19.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.72 | 15.11 | |
| Tangible Book Value Per Share | 13.72 | 15.11 | |
| Enterprise Value Over EBITDA | 1.1 K | 1.1 K | |
| Price Book Value Ratio | 0.98 | 0.81 | |
| Enterprise Value Multiple | 1.1 K | 1.1 K | |
| Price Fair Value | 0.98 | 0.81 | |
| Enterprise Value | 29.3 M | 30.7 M |
Leadership effectiveness at Big Pharma Split is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 10th of February, Big Pharma shows the risk adjusted performance of 0.1538, and Mean Deviation of 1.32. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Big Pharma, as well as the relationship between them.Big Pharma Split Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Big Pharma Split Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Big Pharma price patterns.
Big Pharma Outstanding Bonds
Big Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Big Pharma Split uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Big bonds can be classified according to their maturity, which is the date when Big Pharma Split has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Big Pharma Predictive Daily Indicators
Big Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Big Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2.79 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 14.74 | |||
| Day Typical Price | 14.73 | |||
| Price Action Indicator | (0.02) | |||
| Period Momentum Indicator | (0.01) |
Big Pharma Forecast Models
Big Pharma's time-series forecasting models are one of many Big Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Big Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Big Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.